Last month, Fierce Biotech told you about an unknown number of layoffs due to hit Takeda as the Japanese pharma moves away from early-stage R&D work in adeno-associated virus-based gene therapies ...

Takeda announced the results Saturday morning and will present them at a medical conference for dermatologists in New Orleans over the weekend. STAT+ Exclusive Story. Already have an account?

Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches. Skip to content. Home page Seeking Alpha - Power to Investors.

W ASHINGTON — Takeda Pharmaceuticals has left the biotechnology industry’s main lobbying group, the fourth departure of a major member since December, the company confirmed. “Takeda decided ...

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's biggest drugmaker as the company upped its full-year profit outlook ...

OSAKA, Japan & CAMBRIDGE, Mass., September 18, 2024--Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR ...

Pharmaceutical giant Takeda is shutting down its research and development hub in San Diego that employs 324 as part of a broader restructuring of the business. “This site closure is primarily a ...

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. This week, the medicine, first approved in 2009, was listed as discontinued on the ...

Takeda isn’t saying which dose of TAK-279 it plans to advance to Phase 3, but Plump noted that the clear separation on the 100% clearance measure at 30 mg has the company looking closely at ...

More job cuts are coming at Takeda Pharmaceuticals Inc. just a few weeks after the pharmaceutical giant announced it planned to lay off 641 Massachusetts employees. Boston Business Journal.

Takeda has been struggling to right the ship on Natpara’s manufacturing since it first recalled the medicine in the U.S. back in 2019. As the forecast for Natpara’s revival slipped from 2021 ...

Takeda will pay $4 billion upfront for the drug, which is called NDI-034858 and will be renamed TAK-279, the companies said Tuesday in a statement. Cambridge, ...